JGUA
GILD icon

John G. Ullman & Associates’s Gilead Sciences GILD Stock Holding History

John G. Ullman & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$888K Buy
7,031
+36
+0.5% +$4.74K 0.11% 107
2026
Q1 		$975K Hold
6,995
– – 0.13% 103
2025
Q4 		$859K Hold
6,995
– – 0.11% 109
2025
Q3 		$776K Sell
6,995
-24
-0.3% -$2.73K 0.1% 105
2025
Q2 		$778K Sell
7,019
-2
-0% -$213 0.12% 106
2025
Q1 		$787K Buy
7,021
+1,786
+34% +$184K 0.12% 112
2024
Q4 		$484K Buy
5,235
+257
+5% +$23.1K 0.07% 129
2024
Q3 		$417K Hold
4,978
– – 0.06% 143
2024
Q2 		$342K Buy
4,978
+500
+11% +$33.4K 0.05% 151
2024
Q1 		$328K Buy
4,478
+700
+19% +$53.8K 0.05% 141
2023
Q4 		$306K Sell
3,778
-72
-2% -$5.6K 0.05% 140
2023
Q3 		$289K Sell
3,850
-100
-3% -$7.69K 0.05% 148
2023
Q2 		$304K Hold
3,950
– – 0.05% 149
2023
Q1 		$328K Sell
3,950
-24
-0.6% -$1.99K 0.05% 150
2022
Q4 		$341K Buy
3,974
+124
+3% +$9.82K 0.05% 143
2022
Q3 		$238K Hold
3,850
– – 0.04% 147
2022
Q2 		$238K Buy
3,850
+50
+1% +$3.1K 0.04% 151
2022
Q1 		$226K Hold
3,800
– – 0.03% 157
2021
Q4 		$276K Buy
+3,800
New +$262K 0.04% 144
2020
Q4 		– Sell
-3,665
Closed -$232K – 157
2020
Q3 		$232K Buy
+3,665
New +$254K 0.05% 115
2019
Q4 		– Sell
-4,780
Closed -$303K – 149
2019
Q3 		$303K Sell
4,780
-915
-16% -$59.8K 0.06% 119
2019
Q2 		$385K Buy
5,695
+2,495
+78% +$164K 0.07% 109
2019
Q1 		$208K Sell
3,200
-200
-6% -$13.3K 0.04% 124
2018
Q4 		$213K Buy
3,400
+200
+6% +$14K 0.04% 122
2018
Q3 		$247K Buy
+3,200
New +$242K 0.04% 116
2015
Q2 		– Sell
-2,069
Closed -$203K – 147
2015
Q1 		$203K Buy
+2,069
New +$210K 0.04% 133
2014
Q4 		– Sell
-2,119
Closed -$226K – 146
2014
Q3 		$226K Buy
+2,119
New +$207K 0.04% 136

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

John G. Ullman & Associates's GILD Position: Q2 2026 in Review

John G. Ullman & Associates increased its Gilead Sciences (GILD) stake by 0.51% in Q2 2026, buying an estimated $4.74K and bringing the position to 7,031 shares worth $888K. The position accounts for 0.11% of the portfolio, ranked #107.

John G. Ullman & Associates first reported a position in GILD in Q3 2014 and has held it in 27 quarters since. The position peaked at $975K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • John G. Ullman & Associates held 7,031 shares of Gilead Sciences worth $888K as of Q2 2026.
  • John G. Ullman & Associates bought 36 Gilead Sciences shares in Q2 2026, an estimated $4.74K.
  • Gilead Sciences made up 0.11% of John G. Ullman & Associates's portfolio in Q2 2026, its #107 holding.
  • John G. Ullman & Associates first reported a position in Gilead Sciences in Q3 2014 and has held it in 27 quarters since.
  • John G. Ullman & Associates's Gilead Sciences position peaked at $975K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on John G. Ullman & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.